About Dialog Devices

We have a significant endorsement from the largest healthcare payer in the UK, (the Department of Health, similar to the NIH/SBIR program in USA) with a grant award of £400,000 to get Padd™ selling in primary care. Following successful completion of the clinical feasibility study at the Royal Free Hospital in London, UK, and execution of Series A funding round, we are now in the process of completing Padd™ development, obtaining regulatory approval in Europe and US and marketing the device. We will also advance additional applications for this technology including post-operative monitoring of peripheral interventions and diabetic neuropathy assessment.